drugset / Trial / NCT04058587

A Phase I Trial of Simmitinib in Advanced Solid Tumors

NCT04058587

NaSingle-groupOpen-labelTreatment

Summary

This is an open label, multi-center, phase I study of oral Simmitinib in subjects with advanced solid tumors including gastric cancer.

Timeline

Start
2020-06-08
Primary completion
2023-01-31
Completion
2023-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Simmitinib Small molecule 1 mg Oral

Indications